Exondys 51

Active Ingredient(s): Eteplirsen
FDA Approved: * September 19, 2016
Pharm Company: * SAREPTA THERAPS INC
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Exondys 51 Overview

Eteplirsen (Exondys 51, Sarepta Therapeutics Inc.), also called AVI-4658, is a drug designed for treatment, but not a cure, of some mutations that cause Duchenne muscular dystrophy (DMD), a genetic degenerative muscle disease. Eteplirsen only targets mutations in a region implicated in 13% of DMD cases.[1] After a controversial debate surrounding the efficacy of the drug, eteplirsen received accelerated approval from the US Food and Drug administration in late 2016.[2...

Read more Exondys 51 Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Eteplirsen

Recent Exondys 51 Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Exondys 51: (2 results)

Sorted by National Drug Code

• 60923-284 Exondys 51 50 mg/ml Intravenous Injection by Sarepta Therapeutics, Inc.
• 60923-363 Exondys 51 50 mg/ml Intravenous Injection by Sarepta Therapeutics, Inc.

Other drugs which contain Eteplirsen or a similar ingredient: (1 result)

• ETEPLIRSEN

Related Exondys 51 Topics: